One-carbon metabolism controls colorectal cancer cell state and chemosensitivity through chromatin remodeling
Folate is co-administered with fluoropyrimidines in colorectal cancer to potentiate thymidylate synthase inhibition, yet its therapeutic effects are paradoxically inconsistent across disease and treatment settings. Here we show that one-carbon metabolism remodels epithelial identity before treatment and thereby alters fluoropyrimidine response. Folate restoration shifted colorectal cancer cells…
Research reveals that folate, a one-carbon metabolite, influences colorectal cancer cell behavior and their response to chemotherapeutic drugs through a process called chromatin remodeling. Folate, when combined with fluoropyrimidines, amplifies the inhibitory effect of thymidylate synthase, a key enzyme in DNA synthesis. However, the therapeutic efficacy of folate is variable, depending on the context of treatment.
The study demonstrates that folate influences the epithelial identity of colorectal cancer cells before treatment. When folate is restored, the cells shift from a stem-like to a differentiated state. Conversely, when folate is withheld, the cells become more stem-like. These pretreatment states significantly differ in sensitivity to 5-fluorouracil, a common fluoropyrimidine used in cancer treatment.
Restoring folate increases sensitivity to 5-fluorouracil, while its deprivation or methotrexate increases therapy-induced senescence.
The state-dependent sensitivity is not solely due to differences in proliferation rates. Even when stem-like cells have the highest S-phase occupancy, they are the least responsive to 5-fluorouracil. Mechanistically, folate restoration increases the potential for DNA methylation by altering the histone modification known as H3K27me3.
This modification reorganizes chromatin accessibility and the engagement of transcription factors, while reducing the activity of the WNT signaling pathway, a well-known regulator of cell differentiation.
In human colorectal tissues, the presence of stem-like program activity is higher in tumors compared to normal mucosa, and differentiation program activity is lower in tumors. This pattern is reversed in adenomas, intermediate between tumors and normal tissue. These findings suggest that folate is not merely a cofactor for thymidylate synthase inhibition but plays a crucial role as an instructive metabolic regulator of the epithelial state.
This regulation can stratify the response to fluoropyrimidine drugs, offering potential for personalized cancer treatment strategies.
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.